|
業務類別
|
-- |
|
業務概覽
|
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion. |
| 公司地址
| 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355 |
| 電話號碼
| +1 610 725-1500 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.galeratx.com |
| 員工數量
| 3 |
| Ms. Jennifer Evans Stacey, Esq. |
Chief Legal and Compliance Officer and Secretary |
-- |
28/03/2024 |
| Mr. Jon T. Holmlund, M.D. |
Chief Medical Officer |
-- |
28/04/2022 |
| Dr. J. Mel Sorensen, M.D. |
Director, President and Chief Executive Officer |
-- |
28/03/2024 |
| Mr. Arthur J. Fratamico, R.Ph. |
Chief Business Officer |
-- |
28/04/2021 |
| Mr. Eugene P. Kennedy, M.D. |
Chief Medical Officer |
-- |
27/04/2023 |
| Mr. Christopher Degnan |
Chief Financial Officer and Principal Accounting Officer |
-- |
28/03/2024 |
| Mr. Robert A. Beardsley, PhD |
Chief Operating Officer |
-- |
28/03/2024 |
| Mr. Joel Sussman |
Treasurer |
-- |
10/03/2022 |
| Mr. Mark Bachleda |
Chief Commercial Officer |
美元 475.00K |
27/04/2023 |
|
|
| Mr. Kevin G. Lokay |
Independent Director |
28/03/2024 |
| Dr. Michael F. Powell, PhD |
Chairman of the Board |
28/03/2024 |
| Dr. J. Mel Sorensen, M.D. |
Director, President and Chief Executive Officer |
28/03/2024 |
| Mr. Lawrence M. Alleva |
Independent Director |
28/03/2024 |
| Dr. Emmett Cunningham, M.D.,M.P.H.,PhD |
Director |
28/03/2024 |
| Ms. Linda West |
Independent Director |
28/03/2024 |
|
|
|
|
